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Abstract Cancer stem cells (CSCs) were discovered about
15 years ago in hematopoietic cancers. Subsequently,
cancer stem cells were discovered in various solid tumors.
Based on parallels with normal stem cells, a developmental
process of cancer stem cells follows paths of organized,
hierarchical structure of cells with different degrees of
maturity. While some investigators have reported particular
markers as identification of cancer stem cells, these markers
require further research. In this review, we focus on the
functional genomics of cancer stem cells. Functional
genomics provides useful information on the signaling
pathways which are consecutively activated or inactivated
amongst those cells. This information is of particular
importance for cancer research and clinical treatment in
many respects. (1) Understanding of self-renewal mecha-
nisms crucial to tumor growth. (2) Allow the identification
of new, more specific marker for CSCs, and (3) pathways
that are suitable as future targets for anti-cancer drugs. This
is of particular importance, because today’s chemotherapy
targets the proliferating cancer cells sparing the relatively
slow dividing cancer stem cells. The first step on this long
road therefore is to analyze genome-wide expression-
profiles within the same type of cancer and then between
different types of cancer, encircling those target genes and
pathways, which are specific to these cells.
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Introduction
Since the beginning of microscopic examination of tumors,
many researchers have investigated the relationship be-
tween cancer cells and connective tissue. Rudolf Virchow
was convinced that carcinomas derive from connective
tissue, but soon was disproved by the studies of Cornil,
Thiersch, and Waldeyer. Still, no clue was provided to
explain the invasion of the epithelium. Julius Cohnheim
and Hugo Ribbert hypothesized that invasion of epithelia
was only possible in the case of a primarily altered
connective tissue. Ultimately the stroma determines malig-
nant growth. From 1902, Max Borst finally formulated the
views on tumor-stroma-relationship which are still valid
today. He also postulated interrelationships between tumor
and stroma, which nowadays can be proven using molec-
ular biological approaches.
The term ‘stem cell’ is used to describe cells capable of
both self-renewal and differentiation to one or more
functional lineages [1–3]. Moving down the stem cell
hierarchy, from zygote to fully differentiated cell, the cell
begins to lose pluripotency and becomes more specialized
in morphology and function. Every stem cell, regardless of
type (embryonic or adult), depends on its niche, or micro-
environment. The niche comprises both extrinsic and
intrinsic signals that govern cell fate.
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Cancer is characterized by mutations that cause uncontrolled
cell proliferation and the formation of tumors. The majority
of mutations leading to cancer activate cell-cycle check-
points, which in normal cells prevent hyper-proliferation.
The cancer stem cell (CSC) hypothesis arises in part from the
observation that cancer cell populations are not homoge-
nous. In 1971, Park et al. [4] were able to show that
although tumors arise from a single cell, the cells that
constitute the tumor are not identical to each other. This
evidence of a heterogeneous population led others to
investigate the cellular hierarchy of cancers. The cancer
stem cell hypothesis of tumor development and progression
states that cancer stem cells, like normal stem cells in other
tissues, are a minority of the tumor cell population.
Furthermore, serial transplantation experiments suggest that
they are the only cells that can maintain tumor-growth
indefinitely. The remaining cells, though actively prolifer-
ating and making up the majority of the cells in the tumor,
are also differentiating and destined to die. The self-renewal
properties of CSCs are thus the real driving force behind
tumor-growth. It is uncertain whether these cells are
actually stem cells, or if they were originally normal cells
that have acquired stem cell-like properties. If indeed these
cells do originate from stem cells, then it will be important
to determine whether they are stem cells or progenitor
cells.
The identification of markers that allow the prospective
isolation of CSCs from whole tumor tissues will enable us
to increase our meager understanding of several important
biological properties of CSCs. (a) What is the cell of origin
for a given tumor? (b) What are the signaling pathways that
drive self-renewal and/or differentiation of CSCs? (c) Are
there genes uniquely expressed in CSCs that will allow
targeted therapies to be developed? (d) What are the
mechanisms by which CSCs escape conventional therapies
and can we defeat these mechanisms? Side populations of
cells with stem cell properties have been identified in many
cancers [5–7]. Addressing these questions should lead to
the development of therapies that target the CSC population
and eliminate the ‘engine’ that drives tumors to grow,
invade and seed metastatic lesions. A side population was
identified among thyroid cancer cell lines for the first time
in 2007. Approximately 0.25% of cells in the anaplastic
thyroid carcinoma cell line were shown to be side-
population cells. Other thyroid cancer cell lines harbor an
even smaller percentage of side-population cells [8].
The challenges involved in identifying a CSC population
from a solid tumor, and recent successes in this area are
described in this review, as well as early studies that
represent the first steps toward understanding the biological
properties of cancer stem cells.
Identification of Markers for Isolating Putative Cancer
Stem Cells
The ultimate proof of the existence of a sub-population of
tumor initiating cells came from their ability to recapitulate
the generation of a continuously growing tumor [9]. While
this property has been widely accepted, the question
regarding the origin of CSCs has yet to be answered. CSCs
may have originated from normal stem cells, or more
differentiated cells that have lost their full pluripotent
competence. These cells then re-acquired self-renewal
capacity through multiple mutagenic events, thus making
them the driving force of tumor-growth. The most common
way to identify CSCs in patient-derived tissues is labeling
isolated cells with antibodies against various cell-surface
markers already known in normal stem cells (Table 1).
Cells bearing these cell-surface markers can be isolated by
FACS [10] or magnetic bead columns [11]. These enriched
cell populations are then tested for their ability to initiate
tumorigenesis in immune deficient mice. These cells must
then exhibit all properties of the original cells including a
fully heterogeneous progeny. In contrast to hematopoietic
tumors, the challenge of identifying and characterizing
CSCs in solid tumors is significant. In most cases the
normal tissue developmental hierarchy has not yet been
identified or characterized. This makes the selection of
candidate markers more difficult, and therefore does not
provide the basis for comparison between normal and
malignant cells, as there are no means to identify the cell of
origin. In vivo models of human solid tumors can also be
challenging to achieve, as in some cases orthotopic
injection is not feasible or is technically challenging (e.g.
lung, colon, and bladder cancers). Al-Hajj et al. [12] were
the first to identify and prospectively isolate a minority
subpopulation of cells from a human solid tumor (breast
cancer) that contained all of the in vivo tumor-forming
abilities, while the remaining bulk of cells from those
Table 1 List of known cancer stem cell markers in various tissues
Tumor type CSC phenotype Reference
Breast CD44
+ CD24
−/low Hope et al. [83]
CNS CD133
+ Al-Hajj et al. [12]
Multiple myeloma CD138
− Singh et al. [14]
Melanoma CD20
+ Reynolds and Weiss [22]
Prostate CD44
+ α2β1
+ CD133
+ Fang et al. [25];
Collins et al. [27]
HNSCC CD44
+ Matsui et al. [15]
Colon CD133
+ Dalerba et al. [18]
Colon CD44
+ EpCam
+ Li et al. [17]
CD166
+
Pancreatic CD44
+ EpCam
+ CD24
+ Prince et al. [16]
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cell doses. Similar findings were published for human brain
tumors (GBMs and medulloblastomas). For normal neuro-
nal stem cells it was already known that these cells express
the marker CD133 [13], and it was demonstrated that as
few as 100 CD133
+ cells from human brain tumors could
initiate new tumors in the brains of immune deficient mice,
whereas 100 000 CD133
− cells could not initiate tumors
[14]. It has been shown that multiple myeloma contains a
rare subset of cells, defined by their lack of expression of
the plasma cell marker CD138, that are clonogenic in vitro
and tumorigenic in vivo [15]. More recently, similar
findings have been made for HNSCC [16], pancreatic
cancer [17] and colon cancer [18–20]. The cell-surface
phenotypes of CSC populations from these human solid
tumors are described in Table 1. There have also been
compelling studies in which putative CSCs have been
identified based on their ability to form colonies in vitro.
Sphere-forming ability as a measure of stem cells was first
developed for central nervous system (CNS) cells, where it
has been shown that a subset of cells isolated from human
fetal brain, and subsequently from human CNS tumors,
can form spheres when cultured under the appropriate
conditions [13, 14, 21–24]. These spheres can self renew in
vitro, and differentiate into all of the neuronal lineages,
both in vitro and in vivo. Importantly, it was subsequently
demonstrated for brain tumors that the neurosphere-forming
cells could be prospectively isolated from fresh tissue using
the cell-surface marker CD133. These CD133
+ cells did
indeed initiate brain tumors in vivo, without any in vitro
manipulation, indicating that they do in fact represent CSCs
[23]. Fang et al. [25] have demonstrated that upon culturing
of metastatic melanoma cell suspensions under appropriate
conditions, a subset of cells could be propagated as non-
adherent spheres, which could then be induced to differen-
tiate in vitro and to generate tumors in vivo. However, a
marker has yet to be identified which would allow the
prospective isolation of melanoma sphere-forming cells
from fresh tumors, though the authors provided some
evidence to suggest that CD20 can enrich for the multi-
potent fraction from established sphere cultures and
melanoma cell lines. However, the ability to isolate and
assay sub-populations of cells from tumors that behave as
CSCs is essential before performing characterizations such
as gene expression profiling. Such an approach would
avoid artifacts introduced by culturing cells for extended
periods of time. Another tumor for which CSCs have been
potentially identified based on in vitro assays is prostate
cancer [26]. Cells that are CD44
+ α2β1
+ CD133
+ possess a
significant capacity for self-renewal, differentiation, and
invasiveness in vitro [27]. In this case, it also remains to be
seen whether these cells can reproduce the original tumor
in vivo.
Understanding the Biological Properties of CSC
OnceCSCshavebeenidentified,the realtoilofcharacterizing
their molecular and biological properties begins. The ultimate
aim is identifying ways to specifically target and eradicate
these cells in cancer patients. This is a new field in which we
have barely begun to scratch the surface because of the only
very recent ability to prospectively isolate CSCs from various
tumors. Some of the approaches towards gaining a deeper
understanding of CSC biology that have been reported are
described below.
What is the Biological Significance of Cancer Stem Cells
in Tumor Progression?
If cancer is maintained by CSCs that are characterized by low
ratesofdivisionandproliferation,itisclearthattherapiessuch
as chemotherapy or radiation, which target actively cycling
cells, will be ineffective [28, 29]. Conventional treatments
may cause the tumor to shrink temporarily, but the cells
withstanding these regimens will inevitably lead to recur-
rence of the tumor. Recent studies have shown that CD133
+
cells within the glioma mediate resistance to radiation, at
least in part due to elevated DNA damage response and more
rapid repair of the damaged DNA [30]. The percentage of
CD133
+ cells increased following high dose radiation in
established glioma cell lines, short-term cultures of biopsy
material, and xenograft tumor-bearing mice, resulting in
more aggressive tumors on serial transplantation. It is not
clear why radiation should stimulate CD133
+ cell division.
Very high radiation killed some CD133-expressing cells,
reflecting perhaps a degree of heterogeneity. Others have
reported that CSC-like cells from breast cancer cell lines are
more radio-resistant compared to the rest of breast cancer cells
[31]. These non-adherent sub-populations were grown as
spheroids in mammosphere media and contained a larger
fraction of cells with the CD44
+/CD24
−/low phenotype [12].
When these cultures were irradiated in vitro, the mammo-
spheres were radio-resistant and there was a concomitant
increase in the percentage of CD44
+/CD24
−/low cells. This
would suggest that the relative radioresistance of this subset
may lead to their expansion during the course of radiotherapy.
Other studies have shown that CD133
+ cells isolated from
GBM short-term cultures overexpressed drug resistance
genes, such as breast cancer resistance protein-1 (BCRP1),
DNA mismatch repair genes such as O-6-methylguanine-
DNA methyltransferase (MGMT), as well as showing higher
levels of antiapoptotic gene expression [32]. These CD133
+
cells were also significantly more resistant to chemothera-
peutic agents including temozolomide, carboplatin, paclitaxel
(Taxol), and etoposide (VP16) compared with CD133-
negative cells [33]. In addition, it has been shown that
CD133
+ CSCs isolated from GBMs are resistant to ionizing
Stem Cell Rev (2008) 4:319–328 321 321radiation because they are more efficient at repairing
damaged DNA than the bulk of the tumor cells [30]. Caveats
to this study include the fact that radiation was applied to
single cells separated from each other and their stromal
components. It is not known how similar the response of
these cells would be if they were in their natural setting in
vivo. The radiation response of cells under normoxic
conditions in culture used in this paper may not reflect the
response of cells in the hypoxic environment of a tumor [34].
Similar studies in breast cancer cell lines in vitro have shown
that CD44
+/CD24
− are more radio-resistant and that this
correlated to differences in DNA damage responsiveness
[31]. Recently, Blazek et al. [35]d e m o n s t r a t e dt h a tC D 1 3 3
+
cells sorted from medulloblastoma cell lines are more radio-
resistant and this effect could be enriched by hypoxia. This is
contrary to the clinical findings that medulloblastomas are
much more radio-sensitive than GBMs. The fact that
CD133
+ has been proposed to be the cell of origin for both
tumors illustrates the problems faced by the CSC hypothesis
that focuses too much on the tumor cell and ignores the
contribution of the micro-environment.
The differences in treatment response may be explained
by age; that is, a micro-environment from younger patients
(medulloblastoma) versus micro-environment from older
patients (GBMs). Nevertheless, these shortfalls support the
observation that CSCs are important mediators of resistance
to treatment. The question that remains to be answered is
whether radiation-resistance is a general property of CSCs
in all tumors, and if their presence in human tumors is
predictive of radio-sensitivity.
Global Gene Expression Profiling
One approach to analyse the genome-wide transcription
levels is to compare the CSC profile to that of the non-
CSCs within the tumor, or to the transcriptome of
corresponding normal tissue. Such a study has been
performed for breast cancer, in which the gene expres-
sion profile of the CSC was compared to that of normal
breast epithelium. This analysis led to the identification
of 186 genes which are differentially expressed in the
CSC population. Upon comparison with previously
reported gene signatures in breast cancer, there was a
significant association between the CSC signature and
both overall and metastasis-free survival [36]. The
finding that detectable expression of a specific set of
CSC-related genes upon analysis of whole tumor tissue
correlates with prognosis suggests that more aggressive
tumors may contain a relatively higher percentage of CSC,
possibly caused by mutations that arrest cells in an
immature state of differentiation. Indeed, differentiation
status correlates with prognosis in many cancers. A similar
approach was taken by Shipitsin et al. [37]. In this study
breast tumor cells with a CSC phenotype were analyzed
for their global gene expression profile compared to the
non-tumorigenic cells from the same tumors. The profiles
found indicated that cells of the CSC phenotype expressed
stem/progenitor-associated genes whilst the non-CSC
expressed differentiation-associated genes. They also
found a correlation of the gene expression signature of
CSCs with patient clinical outcome. Furthermore, they
identified a signaling pathway (TGF-β) specifically active
in the CSC population, and found that inhibition of this
p a t h w a yi nv i t r ol e dt od i f f e r e n t i a t i o n .T h e s eo b s e r v a t i o n s
once again demonstrate that purification of CSC allows
the identification of biological properties of cells that are
unique and that may otherwise not have been revealed.
They also found that CD24
+ cells in one patient sample
had an additional genetic change not present in the
CD44
+/CD24
- cells. The authors state that it has not been
proven that the CD24
+ cells are the progeny of the CD44
+/
CD24
− cells; however this is not the case. In the study by
A l - H a j je ta l .[ 12], it was shown that tumors grown from
the CD44
+/CD24
− tumorigenic population give rise again
to the original tumor heterogeneity, including the CD24
+
cells. Thus the finding of genetic changes present in the
CD24
+ cells but not in the CD44
+ CD24
− population, but
not vice versa, does not question the validity of the CSC
hypothesis as suggested by Shipitsin et al. It is conceiv-
able that additional genetic changes could take place in
differentiating progenitors that are the progeny of the
CSC, or that clonal evolution could occur within the CSC
population itself as the tumor grows and the CSC
population expands. Thus, although the authors state that
their data calls the CSC hypothesis into question, in our
opinion their data elegantly supports it.
Comparison of CD133 Gene Expression Profiles
Recently some studies were published, focusing on genome-
wide expression profiling in various cancers. In this review,
we have compared the data-sets of 2 different studies that
have provided genome-wide expression data from CD133
+
cells. This approach was of particular interest in regard of
our own work, where we analyze CD133
+ cells from human
glioblastomas (data not published). Both studies presented
about 100 candidate-genes, which were differentially
expressed in the CD133
+-fraction [38, 39]. As illustrated
by the Venn-diagram in Fig. 1a, the overlap consists of just
10 genes, shown to be differentially regulated between the
studies. Despite the relatively small datasets and the different
ways of analyses in the original studies, the public available
Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) provides evidence that 9 out of the 10 candidate
genes have been shown to form an interactive network
directly interact with each other (Fig. 1b). Upon expansion of
322 Stem Cell Rev (2008) 4:319–328the network it becomes obvious that these target genes are
positioned at the interface between proliferative pathways
(JAK/STAT) and differentiating pathways (HOX, PBX,
MEIS, GATA2) (Fig. 1c). Of importance in this cascade is
the gene KIT. This gene encodes the receptor for stem cell
factor (SCF) which is the human homolog of the proto-
oncogene C-KIT.M u t a t i o n si nKIT are associated with the
outcome and progression in gliomas and acute myelogenous
leukemia [40–42]. Mesoderm specific transcript homolog
(MEST) does not connect to the proposed network of the
other 9 genes. Despite that, in normal cells MEST is
imprinted, and a loss of imprinting of MEST has been
reported to associate with various cancers [43, 44].
Performing DAVID [45] annotation and KEGG [46]p a t h -
way analysis with the respective data-sets revealed signifi-
cant enriched scores of numerous pathways. Amongst these
are: Glycolisis/Gluconeogenesis (HSA00010), Cell Commu-
nication (HSA01430), Proteasome (HSA03050), Cell-Cycle
(HSA04110),WNT-Signaling(HSA04310),TGF-β-Signaling
(HSA04350) and Apoptosis (HSA04210). All of these path-
ways are known to play significant roles in various types of
cancer development and progression. Proteins of all of these
Fig. 1 Comparison of datasets
of two independent genome-
wide expression analyses of
CD133
+ CSCs. a Venn diagram
illustrating the common genes in
CD133
+ cells. b nine of 10
genes from this common dataset
form a network, as retrieved
from STRING search (http://
www.string.embl.de) c An ex-
panded view of the interactions
facilitated by these 10 genes
reveals that the receptor thyrosin
kinase KIT connects prolifera-
tive pathways (JAK/STAT) to
morphogenetic pathways (HOX,
GATA2, MEIS1)
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these pathways intwo independent genomic approachesover-
represented in the respective stem cell population makes it
very tempting to speculate on the enormous significance of
this small subpopulation of cells for the classification of
the cancer. Besides the significance of these pathways in
cancer, these pathways also play important roles in stem cells
[47, 48]. Comparative transcription profiling of normal and
cancer stem cells is the way forward if we are to increase our
meagre understanding of the molecular mechanisms under-
lying CSC proliferation.
Identification of Cancer Relevant Pathways
A microarray-based differential gene expression profile
between side-population cells and non side-population cells
has revealed several stem cell-associated genes (ABCG2,
MYC, JUN, FZD5, HES1 and JAG1) as up-regulated in
side-population cells. However, both side-population and
non-sidepopulation cells derived from thyroid cancer cell
lines can form tumors when injected into nude mice [8].
This finding suggests either today’s markers are not a gold
standard for isolating CSCs from bulk-tumor or that there is
a delicate equilibrium between the tumor-cell populations
maintained by autocrine and/or paracrine signaling. The
cancer stem cell theory couples/reconciles the idea that
stem cells are responsible for cancer with the hypothesis
that distinct mutations in signaling pathways are involved
in tumorgenicity. Signaling pathways associated with ES
cell proliferation and differentiation are particularly impor-
tant to the cancer stem cell theory [47, 48]. For example,
the Wnt/β-catenin pathway is involved in the maintenance
and self-renewal of hematopoietic stem cells and progenitor
cells; overexpression of WNT protein is also seen in
numerous human cancers [49]. Moreover, Sonic-hedgehog,
which is involved in maintaining hematopoietic stem cells
and progenitor cells as well as brain development, is
associated with brain tumors [50].
Identification of Self-Renewal Signaling Pathways in CSCs
In addition to gene expression profiling, CSCs have been
demonstrated to express known stem-cell-associated genes
by other methods, including qRT-PCR and immune-staining.
Head and neck squamous cell carcinoma (HNSCC) CSCs
differentially express BMI1 in the CD44
+ population
compared to the CD44
− population, and pancreatic CSCs
differentially express SHH. Studies have yet to be con-
ducted to determine whether these genes are functionally
important for formation of these human tumor types. Their
known roles in the self-renewal of normal tissue stem cells
and other CSC populations suggest that they may also be
important in these tumors. For example, in mice, BMI1 is
essential for the self-renewal of hematopoietic and neural
stem cells [51, 52] and has been shown to be required for
the self-renewal of leukemic stem cells [53]. BMI1 is over-
expressed in human AML compared to normal bone
marrow. The Hedgehog pathway has long been implicated
in many different kinds of cancers [54] and more recently
has been related specifically to human CSCs from multiple
myeloma [55], breast cancer [56] and gliomas [57, 58]. The
WNT signaling pathway has also been implicated in both
stem cell self-renewal and cancer [59–61], and has been
shown specifically to be active in the CSC population of
human CML blast crisis patients [62]. BMPs and their
antagonists are known to play important roles in regulating
homeostasis of various organs and tissues via the control of
differentiation, proliferation and apoptosis [63, 64]. They
have also been implicated in several cancers [63, 65].
Piccirillo et al. [66] recently demonstrated that BMPs, in
particular BMP4, depleted the brain tumor stem-cell
population in vitro via a pro-differentiation effect, and
inhibited tumorigenicity in vivo [66]. There are several
other signaling pathways including the NOTCH, PTEN,
and HOX pathways [67, 68] that have known roles in
maintenance and/or control of normal and CSC compart-
ments in mice, as well as being implicated in cancer. To
date there is no conclusive evidence of a possible functional
role specifically in human CSC populations. The discovery
of signaling pathways that play a functional role in CSC
self-renewal is extremely important from a therapeutic
perspective, as some of these pathways have known
chemical inhibitors (e.g. the Hh pathway can be inhibited
by cyclopamine treatment), or function as inducers of
differentiation (e.g. BMPs) [48, 69].
Identification of a CSC Micro-Environment
Normal stem cells are dependent upon their micro-
environment, or ‘niche’ to maintain their ability of
asymmetric division [70]. It is well known that a large
component of solid tumors is made up of stromal cells and
may consist of a variety of different cell types, including
inflammatory cells, vascular endothelial cells and fibro-
blasts. In fact these stromal cells are essential for tumor-
growth, mediated either through direct cell contacts and/or
secreted factors [71, 72]. In an effort to understand the role
of the micro-environment, Sneddon et al. [63] conducted a
study where they compared the gene expression profiles of
neoplastic stromal cells versus stromal cells from non-
tumor skin. This led to identification of GREM1 and FST,
which are BMP antagonists, both genes are differentially
expressed in the “tumor-stroma”.F u r t h e r m o r e ,BMP2 and
BMP4 were expressed in SCC tumor cell nests, and
GREMLIN1 was able to prevent inhibition of SCC growth
by BMP4 in vitro. GREMLIN1 is expressed by stromal
324 Stem Cell Rev (2008) 4:319–328cells in diverse human carcinomas, but not in corre-
sponding normal tissues. This study suggests that the
expression of factors by the tumor-micro-environment that
regulate self-renewal may be a general feature of human
c a n c e r ,a n di d e n t i f i c a t i o no fs u c hf a c t o r sm a yl e a dt ot h e
identification of potential therapeutic targets. Prince et al.
[16] demonstrated that the CSC-containing population in
well and moderately differentiated HNSCC is physically
located adjacent to stroma, further indicating that there
may be important interactions between the CSC and the
stroma in carcinomas. Brain tumor stem cells also appear
to interact with a niche. Mouse neural stem cells have
been shown to lie within a vascular niche in which
endothelial cells regulate stem cell self-renewal [73, 74].
Therefore Calabrese et al. [75] investigated whether the
CD133
+/Nestin
+ cells that contain the CSC fraction are
associated with vasculature and found that indeed they
are. Furthermore, endothelial cells supply secreted factors
that maintain the brain tumor stem cells in vitro in a self-
renewing and undifferentiated state. Finally, increasing the
number of endothelial cells or blood vessels in xenografts
expanded the CSC population and accelerated its growth,
while anti-angiogenic therapies depleted the CSCs from
the xenografts and arrested tumor-growth. Thus the
concept of the role of a CSC niche and the potential of
inhibiting its interactions with CSC populations appears to
be an approach with a great deal of therapeutic potential,
both for disease treatment and for chemoprevention [76].
Furthermore, the identification of the CSC niche should
allow the development of in vitro assay systems that mimic
the in vivo environment, providing more rapid results than
the currently cumbersome and time-consuming in vivo
assays, as well as allowing manipulations that are currently
not feasible with in vivo systems. Ultimately, an under-
standing of the CSC niche in addition to the CSCs
themselves for each different type of cancer should lead to
a better understanding of the signals that are important for
CSC self-renewal and/or differentiation in those cancers.
Are CSCs Selectively Resistant to Conventional Therapies?
Normal stem cells are known to be relatively quiescent,
resistant to drugs and toxins through the expression of drug
efflux pumps, and have an active DNA-repair capacity and
resistance to apoptosis [77]. If CSCs share many of the
properties of normal stem cells, as is hypothesized, this
means that conventional chemo and radiation therapies,
which target rapidly cycling cells, will lead to reduction of
the tumor through killing of the progeny of the CSCs,
but the CSCs themselves will remain unaffected. Further-
more, the presence of drug efflux pumps and DNA-repair
mechanisms will make them additionally resistant to these
forms of therapy. Several studies have been done which
support this hypothesis. In the hematopoietic system, both
normal and leukemic stem cells are largely quiescent and
express drug efflux molecules such as ABCG2 [78, 79],
and AML stem cells are selectively resistant to both
daunorubicin and Ara-C [80, 81]. More recently, it was
shown that CD133
+ brain tumor stem cells are selectively
resistant to radiation, both in vitro and in vivo, and the
mechanism for this resistance was shown to be through
preferential activation of the DNA damage checkpoint
response and an increase in DNA-repair capacity [30]. By
understanding the mechanisms that enable CSCs to resist
conventional therapies, it may be possible to find ways to
manipulate these cells to become sensitive to these
therapies.
Clinical Implications of Cancer Stem Cells
If proven to be true, the cancer stem cell theory could
profoundly affect how cancer is treated. The identification
of cancer stem cells provides a specific target for
chemotherapy and drugs, and it may even dictate the
aggressiveness of the treatment. Currently, many common
chemotherapy and radiation protocols target all dividing
cells, regardless of whether or not they are cancerous.
However, if the disease is due to cancer stem cells, this
could be the wrong approach, because cancer stem cells are
relatively quiescent, they may survive treatment intended to
kill dividing cells. In this case, the patient may appear to
have made a full recovery only to relapse years later when
the cancer stem cells are reactivated. If this scenario is true,
it is possible that today’s cancer therapies are merely
Fig. 2 Acquired capabilities of cancer stem cells. We suggest that
most if not all cancer stem cells have acquired the same set of
functional capabilities during their development, albeit through
various mechanistic strategies. These properties provide potential
leads for future cancer stem cell driven therapies
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the root of the problem: cancer stem cells. Development of
drugs that specifically target cancer stem cells may render
cancer treatment more successful and efficient, and less
toxic to the patient. For example, stem cells have active
ATP-binding cassette transporters of specific types, which
may increase the resistance of cancer stem cells to typical
treatment options. Stem cell-specific targets such as these
could be very useful in the design of new therapies.
Although the cancer stem cell hypothesis is still being
debated, the implications for future therapies are great, and
it may even be able to change the way we diagnose and
treat the disease.
Conclusions
The CSC field, particularly in the area of solid tumors, is
still in its prime. On the basis of the highly recognized
hallmark-paper by Hannahan & Weinberg [82] we suggest
a model highlighting the properties that are currently
viewed as important for tumor growth, and that may
represent therapeutic targets (Fig. 2). We are still in the
very technically challenging stage of identifying the
methods that will allow us to prospectively isolate CSCs
from various solid tumors, and most importantly, to
demonstrate in vivo that the populations we are looking at
are truly CSCs. In the cases where CSCs have been
identified, early studies have already shown that they
possess important biological properties that directly relate
to patient outcome. The breast CSC gene expression profile
was shown to correlate with patient prognosis, and the brain
CSC has been shown to be specifically resistant to radiation
through DNA damage repair. In addition, specific signaling
pathways have been shown to play a functional role in CSC
self-renewal and/or differentiation, and early studies indi-
cate that CSCs are associated with a micro-environmental
niche. The mechanisms by which CSCs evade current
therapies are being elucidated. These types of studies
should lead to a better understanding of the molecular
mechanisms controlling self-renewal and differentiation.
The advent of new high-throughput technologies and the
ability to apply them to small numbers of cells should lead
to the identification of CSC-specific targets. The develop-
ment of methods for the prospective isolation of CSCs is
thus the first step, which then paves the way for a variety of
approaches that could ultimately lead to CSC-specific
therapies for cancer treatment.
The CSC hypothesis and emerging data on the functional
properties of these cells have obvious therapeutic implica-
tions and raise the question whether we are targeting the
right cells. Available data also suggest alternative strategies
for homing on in CSCs in solid tumors, whereas animal
studies suggest that CSCs can be induced to stop
proliferating in a way that resembles differentiation of
normal stem cells. Anti-cancer approaches aimed at the
CSCs may not be suitable for all clinical settings. In GBM
tumors, resistance to treatment is common to most cells
within the cancer cell pool, so even proliferating cells
survive the conventional treatments. In these cases, efficient
control of the proliferating cells should be the primary
objective, with targeting CSCs being a secondary aim.
Although many uncertainties remain regarding the nature of
CSCs in the CNS, accumulating data have demonstrated
that there is a functional heterogeneity among the cancerous
cells constituting a brain tumor. The focus of future
research may therefore be to develop treatments that are
modified according to this heterogeneity.
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